RNA Therapeutics Market Research Report 2023: Focus on mRNA Therapeutics, RNA Interference, Antisense Oligonucleotides - Global Forecast to 2028
31 janv. 2024 05h59 HE
|
Research and Markets
Dublin, Jan. 31, 2024 (GLOBE NEWSWIRE) -- The "RNA Therapeutics Market by Product (Vaccines, Drugs), Type (mRNA Therapeutics, RNA Interference, Antisense Oligonucleotides), Indication (Infectious...
Global mRNA Therapeutics Market Set to Reach $21 Billion by 2028 Despite Decline, Fueled by Next-Gen Drugs
25 janv. 2024 09h54 HE
|
Research and Markets
Dublin, Jan. 25, 2024 (GLOBE NEWSWIRE) -- The "mRNA: Therapeutics and Global Markets" report has been added to ResearchAndMarkets.com's offering.The global market for mRNA therapeutics reached $60...
mRNA Therapeutics Market to Reach USD 45.40 Billion by 2030 as a Result of Advances in Technology, Particularly in Gene Editing and Delivery Systems | Research by SNS Insider
30 mars 2023 11h28 HE
|
SNS Insider pvt ltd
Pune, March 30, 2023 (GLOBE NEWSWIRE) -- The size of mRNA therapeutics market was valued at USD 39.40 billion in 2022 and is projected to reach USD 45.40 billion by 2030, with a compound annual...
Global mRNA Therapeutics Market Size To Grow USD 38.15 Billion By 2030 | CAGR of 2.2%
23 mars 2023 13h30 HE
|
SPHERICAL INSIGHTS LLP
New York, United States , March 23, 2023 (GLOBE NEWSWIRE) -- The Global mRNA Therapeutics Market Size to Grow from USD 33.60 Billion in 2021 to USD 38.15 Billion by 2030, at a Compound Annual Growth...
BioNTech gibt Gründung eines interdisziplinären mRNA-Exzellenzzentrums für gemeinsame Forschung mit dem Weizmann Institute of Science in Israel bekannt
01 mars 2023 08h00 HE
|
BioNTech SE
JERUSALEM, Israel, 1. März 2023 – BioNTech SE (Nasdaq: BNTX, „BioNTech“, „das Unternehmen“) gab heute bekannt, dass das Unternehmen eine Absichtserklärung (Memorandum of Understanding) mit dem...
BioNTech Announces Establishment of Interdisciplinary mRNA Excellence Center to Conduct Research Jointly with Scientists from Weizmann Institute of Science in Israel
01 mars 2023 08h00 HE
|
BioNTech SE
JERUSALEM, Israel, March 1, 2023 – BioNTech SE (Nasdaq: BNTX, “BioNTech”, “the Company”) announced that the Company and the Weizmann Institute of Science (“Weizmann Institute”) signed a Memorandum of...
BioNTech stärkt Produktionsstandort Marburg durch erste unternehmenseigene Plasmid-DNA-Herstellungsstätte
02 févr. 2023 06h45 HE
|
BioNTech SE
Plasmide sind ein zentrales Ausgangsmaterial für die Herstellung von mRNA- und zellbasierten MedikamentenBioNTech stellt mit unternehmenseigener Plasmid-Herstellungsstätte die Produktion von zentralem...
BioNTech Strengthens Manufacturing Capabilities with First In-House Plasmid DNA Manufacturing Facility
02 févr. 2023 06h45 HE
|
BioNTech SE
Plasmids are an important starting material for the manufacturing of mRNA- and cell-based drugsThe new plasmid manufacturing facility aims to increase BioNTech’s autonomy and flexibility in...
mRNA therapeutics and mRNA vaccines market is anticipated to grow at a steady pace, till 2035, claims Roots Analysis
01 févr. 2023 10h30 HE
|
Roots Analysis
London, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of the “mRNA Therapeutics and mRNA Vaccines Market, 2022–2035” report to its list of offerings. The mRNA...
The mRNA synthesis and mRNA manufacturing market is projected to be worth USD 1.5 billion by 2035, claims Roots Analysis
26 janv. 2023 11h25 HE
|
Roots Analysis
London, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “mRNA Synthesis and mRNA Manufacturing Services Market (2nd Edition), 2022–2035” report to its list of...